Zoom: Urano has been saying since September of last year that he prefers "small molecules" over "recombinant." That has been my argument, not that he isn't even testing recombinant.

You didn't ask the right question. You should have asked, "Do you still prefer small molecules over recominant MANF in the treatment of diabetes?" That would have provided an answer to our debate. I've never questioned whether recombinant was being tested, just that it wasn't "preferred."